BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25143186)

  • 1. Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiency.
    Panch SR; Yau YY; Kang EM; De Ravin SS; Malech HL; Leitman SF
    Transfusion; 2015 Feb; 55(2):265-74. PubMed ID: 25143186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase--deficient severe combined immunodeficiency disease patients.
    Sekhsaria S; Fleisher TA; Vowells S; Brown M; Miller J; Gordon I; Blaese RM; Dunbar CE; Leitman S; Malech HL
    Blood; 1996 Aug; 88(3):1104-12. PubMed ID: 8704221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
    Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized peripheral blood progenitor cell mobilization for autologous hematopoietic cell transplantation in children with high-risk and refractory malignancies.
    Furlong E; Jensen J; Woodard M; Griffiths K; Knight G; Sturm M; Kerr F; Gough H; Bear N; Carter TL; Cole CH; Kotecha RS; Ramachandran S
    Pediatr Transplant; 2020 Feb; 24(1):e13602. PubMed ID: 31631445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
    Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait.
    Panch SR; Yau YY; Fitzhugh CD; Hsieh MM; Tisdale JF; Leitman SF
    Transfusion; 2016 May; 56(5):1058-65. PubMed ID: 27167356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma.
    Bogucka-Fedorczuk A; Czyz A; Kalicińska E; Sawicki M; Laszkowska-Lewko M; Wicherska-Pawłowska K; Rybka J; Szeremet A; Prajs I; Szymczak D; Wróbel T
    J Clin Apher; 2020 Aug; 35(4):246-254. PubMed ID: 32298020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield.
    Furundarena JR; Uranga A; Alkorta A; González C; Javier Ferreiro J; Rey M; Aragón L; Urreta I; Emparanza JI; Redín H; Garrido A; Araiz M
    Int J Lab Hematol; 2020 Apr; 42(2):170-179. PubMed ID: 31830371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency.
    Tichelli A; Passweg J; Hoffmann T; Gregor M; Kühne T; Favre G; Wodnar-Filipowicz A; Gratwohl A
    Br J Haematol; 1999 Jul; 106(1):152-8. PubMed ID: 10444178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant.
    Jaime-Pérez JC; Gómez-Galaviz AC; Turrubiates-Hernández GA; Picón-Galindo E; Salazar-Riojas R; Méndez-Ramírez N; Gómez-Almaguer D
    Cytotherapy; 2020 Mar; 22(3):144-148. PubMed ID: 32057615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients.
    Majado MJ; Minguela A; González-García C; Salido E; Blanquer M; Funes C; Insausti CL; García-Hernández AM; Moraleda JM; Morales A
    J Clin Apher; 2009; 24(1):12-7. PubMed ID: 19170164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease.
    Tormey CA; Snyder EL; Cooper DL
    Transfusion; 2008 Sep; 48(9):1930-3. PubMed ID: 18513256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days.
    Khouri J; Rybicki L; Majhail N; Kalaycio M; Copelan E; Pohlman B; Hill B; Dean R; Lazaryan A; Hamilton B; Andresen S; Sobecks R; Bolwell B; Liu H
    J Clin Apher; 2018 Jun; 33(3):303-309. PubMed ID: 29134688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
    Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte-colony-stimulating factor.
    Chen J; Burns KM; Babic A; Carrum G; Kennedy M; Segura FJ; Garcia S; Potts S; Leveque C
    Transfusion; 2014 Jan; 54(1):203-10. PubMed ID: 23763340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.